Bioequivalence of Two Mixtard® 30 Formulations in Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-05-31

Study Completion Date

2006-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial is conducted in Europe. The aim of this trial is to to test for bioequivalence between two formulations of Mixtard® 30 in healthy subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes

NCT01467401

Diabetes Diabetes Mellitus, Type 2

COMPLETED PHASE4

Bioequivalence of Two Insulatard® Formulations in Healthy Subjects

NCT01486901

Diabetes Healthy

COMPLETED PHASE1

Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs

NCT01486862

Diabetes Diabetes Mellitus, Type 2

COMPLETED PHASE4

Comparison of Two Biphasic Insulin Aspart 30 Formulations (Current and New Formulation) in Healthy Volunteers

NCT01487811

Diabetes Healthy

COMPLETED PHASE1

Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes

NCT01526980

Diabetes Diabetes Mellitus, Type 2

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Formulation A

Group Type EXPERIMENTAL

biphasic human insulin 30

Intervention Type DRUG

Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits

Formulation B

Group Type ACTIVE_COMPARATOR

biphasic human insulin 30

Intervention Type DRUG

Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

biphasic human insulin 30

Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Considered generally healthy upon completion of medical history and physical examination as judged by the Investigator
* Body Mass Index (BMI) between 18.0 and 27.0 kg/m\^2, inclusive
* Non-smoker, defined as no nicotine consumption for at least one year
* Fasting plasma glucose below or equal to 100 mg/dL (5.6 mmol/L)

Exclusion Criteria

* Previous participation in this trial or other clinical trials within the last 3 months
* Body weight above 87.5 kg
* Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures (intrauterine device (IUD) that has been in place for at least 3
* History of alcohol or drug abuse

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No